News

RADIOMEDIX AWARDED $2.0 M NCI SBIR DIRECT-TO-PHASE II GRANT TO DEVELOP DRUG FOR TARGETED ALPHA-EMITTER THERAPY

Posted by RadioMedix . on

RADIOMEDIX AWARDED $2.0 M NCI SBIR DIRECT-TO-PHASE II GRANT TO DEVELOP DRUG FOR TARGETED ALPHA-EMITTER THERAPY

RadioMedix, a clinical-stage biotechnology company developing radiotheranostic drugs, announced that it has been awarded a $2.0M Phase Direct to Phase II Small Business Innovation Research (SBIR) grant from the National Cancer Institute at the US National Institutes of Health . The grant supports Phase I/II clinical development of innovative alpha-emitter labeled peptide, AlphaMedixTM,  for therapy of somatostatin receptor positive neuroendocrine tumors. RadioMedix successfully completed Phase I and Phase II NCI SBIR Contracts  focused on the dose escalation and safety studies of AlphaMedix in PRRT-naïve neuroendocrine patients. The Phase II SBIR funding will be used to evaluate additional safety and efficacy...

Read more →

Izabela Tworowska, RadioMedix CSO, selected as Semi-Finalists of 2021 Women’s Venture Competition!

Posted by RadioMedix . on

Izabela Tworowska, RadioMedix CSO, selected as Semi-Finalists of 2021 Women’s Venture Competition!

The AIM-HI Accelerator Fund just announced 10 semi-finalists for the 2021 Women’s Venture Competition! These oncology companies have been selected from among an exceptional pool of applications submitted globally by women scientist-entrepreneurs. Decision making was led by a selection committee comprised of world-class key opinion leaders, life sciences industry experts, investors, and entrepreneurs. The Women’s Venture Competition is a first-of-its-kind program that provides funding, coaching, and networking opportunities to women-led oncology start-ups. The chosen semi-finalists are advancing to a virtual competition being conducted on August 2, 2021. The winning company, to be determined by a word-class judging committee, will receive a total...

Read more →

FDA Authorization of IND for 225Ac-PSMA I&T Targeted Alpha Therapy for Castration Resistant Prostate Cancer

Posted by RadioMedix . on

FDA Authorization of IND for 225Ac-PSMA I&T Targeted Alpha Therapy for Castration Resistant Prostate Cancer

Houston-Texas August 2nd, 2021 Excel Diagnostics and Nuclear Oncology Center (EDNOC), a premier Diagnostic Imaging and Radioligand Therapy   center in Houston, Texas announces approval of its physicians sponsored Investigational New Drug (IND) application for providing Targeted Alpha Therapy (TAT) with 225Ac-PSMA I&T for metastatic Castration Resistant Prostate Cancer (mCRPC).  “We are glad to be able to make this game changing drug available to our patients suffering from mCRPC.  Excel Diagnostics and Nuclear Oncology Center has been a pioneer in bringing new targeted Radioligand Therapies such as Lu-177 DOTATATE, and Lu-177 PSMA to serve our patients in the United States. The...

Read more →

RadioMedix wins 2020 TechConnect Innovation Award and pitched at Virtual TechConnect Business Summit

Posted by RadioMedix . on

RadioMedix wins 2020 TechConnect Innovation Award and pitched at Virtual TechConnect Business Summit

Houston (TX), Jan. 04, 2021 (GLOBE NEWSWIRE) -- RadioMedix Inc. Houston-based clinical-stage radiopharmaceutical company is proud to announce that the company was selected for the 2020 TechConnect Innovation Award. The annual TechConnect Business Innovation Awards program recognizes the top 15% of submitted technologies as ranked by the selection committee in multiple categories from the Energy, Nanomaterials, Health and Medicine, AI, Robotics, and others. The Summit is co-organized by SBIR/STTR Innovation Program and co-located with Defense Innovation Summit..     RadioMedix received the TechConnect Innovation Award based on the early results of the clinical studies of the targeted alpha-emitter therapy of cancer and its potential...

Read more →

FDA has issued Drug Master File for ITM’s Gallium Generator GeGant®

Posted by RadioMedix . on

FDA has issued Drug Master File for ITM’s Gallium Generator GeGant®

Garching/Munich, Germany, and Houston, Texas, U.S., December 08, 2020: ITM Isotopen Technologien München AG (ITM), a biotechnology and radiopharmaceutical group of companies, and RadioMedix Inc., a clinical stage biotechnology company, today announced that the U.S. Food and Drug Administration (FDA) has issued the Drug Master File (DMF no. 34938) for ITM’s next generation Germanium-68/Gallium-68 (68Ge/68Ga) Generator, distributed under the brand name GeGant®.The DMF will allow parties interested in developing new drugs for the U.S. market to refer to the DMF and use GeGant® in clinical tests for radiopharmaceuticals and in other settings. The GeGant® Generators will be manufactured at the...

Read more →